In fact, a recent study[69] demonstrated alterations of Hh pathway gene expression in a subpopulation of CML-CP patients: the negative modulators GLI3 and SUFU genes were down-regulated and the Hh target genes CCNB2, STIL, FOXM1 and GLI1 genes were up-regulated. The gene discussed is GLI1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.